Coagulation parameters in HIV

Follow-up of thrombophilia, inflammation and markers of cardiovascular disease in HIV-1 patients on long-term cART

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20034

Enrollment

Registered

2019-07-18

Start date

2019-07-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV, thrombophilia

Interventions

Questionnaire and blood sampling

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion in the original INF-BEAST study

Exclusion criteria

Exclusion criteria: Declining informed consent to participate in the INF-BEAST2 study

Design outcomes

Primary

Measure	Time frame
Plasma levels of following markers: - FVIII - Anti-thrombin - Protein C antigen - Protein S antigen - Free protein S - Fibrinogen - Lupus anticoagulans - Von Willebrand factor - D-dimer	—

Secondary

Measure	Time frame
- Lipid plasma levels (including cholesterol, HDL- and LDL cholesterol and triglycerides) - The occurrence of cardiovascular events (including myocardial infarction, cerebrovascular accidents, peripheral arterial disease, arterial thrombosis) and venous thrombosis at any site	—

Contacts

Public ContactSoerajja Bhoelan

UMCG

b.s.bhoelan@umcg.nl0652724617

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)